AZD3965   Click here for help

GtoPdb Ligand ID: 10605

Synonyms: AZD-3965
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: AZD3965 is an inhibitor of the monocarboxylate (lactate) transporter MCT1 (SLC16A1) [2]. Eklevated MCT1 expression has been reported in a range of solid tumours [4] and it is functionally essential in certain lymphomas which are highly dependent on the glycolytic metabolic pathway [3]. It appears that cancer cells exploit MCT1 to efflux lactate so as to prevent intracellular acidification so as to prevent metabolic catastrophe. MCT1 inhibitors are being investigated for their potential to inhibit glycolysis and tumour growth.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 150.69
Molecular weight 515.15
XLogP 2.87
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(c1c(Cc2c(C)[nH]nc2C(F)(F)F)sc2c1c(=O)n(c(=O)n2C(C)C)C)N1OCC(C1)(C)O
Isomeric SMILES O=C(c1c(Cc2c(C)[nH]nc2C(F)(F)F)sc2c1c(=O)n(c(=O)n2C(C)C)C)N1OC[C@@](C1)(C)O
InChI InChI=1S/C21H24F3N5O5S/c1-9(2)29-18-14(16(30)27(5)19(29)32)13(17(31)28-7-20(4,33)8-34-28)12(35-18)6-11-10(3)25-26-15(11)21(22,23)24/h9,33H,6-8H2,1-5H3,(H,25,26)/t20-/m0/s1
InChI Key PRNXOFBDXNTIFG-FQEVSTJZSA-N
No information available.
Summary of Clinical Use Click here for help
AZD3965 was advanced to Phase 1 first-in-human clinical evaluation in cancer patients (NCT01791595).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01791595 A Phase I Trial of AZD3965 in Patients With Advanced Cancer Phase 1 Interventional Cancer Research UK